RT Journal Article
SR Electronic
T1 A genome epidemiological study of SARS-CoV-2 introduction into Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.01.20143958
DO 10.1101/2020.07.01.20143958
A1 Sekizuka, Tsuyoshi
A1 Itokawa, Kentaro
A1 Hashino, Masanori
A1 Kawano-Sugaya, Tetsuro
A1 Tanaka, Rina
A1 Yatsu, Koji
A1 Ohnishi, Asami
A1 Goto, Keiko
A1 Tsukagoshi, Hiroyuki
A1 Ehara, Hayato
A1 Sadamasu, Kenji
A1 Taira, Masakatsu
A1 Shibata, Shinichiro
A1 Nomoto, Ryohei
A1 Hiroi, Satoshi
A1 Toho, Miho
A1 Shimada, Tomoe
A1 Matsui, Tamano
A1 Sunagawa, Tomimasa
A1 Kamiya, Hajime
A1 Yahata, Yuichiro
A1 Yamagishi, Takuya
A1 Suzuki, Motoi
A1 Wakita, Takaji
A1 Kuroda, Makoto
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/02/2020.07.01.20143958.abstract
AB Background After the first case of COVID-19 in Japan on 15 January 2020, multiple nationwide COVID-19 clusters were identified by the end of February. The Japanese government focused on mitigating emerging COVID-19 clusters by conducting active nationwide epidemiological surveillance. However, an increasing number of cases appeared until early April, many with unclear infection routes exhibiting no recent history of travel outside Japan. We aimed to evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequences from COVID-19 cases until early April and characterise the genealogical networks to demonstrate possible routes of spread in Japan.Methods Nasopharyngeal specimens were collected from patients and a quantitative reverse transcription polymerase chain reaction testing for SARS-CoV-2 was performed. Positive RNA samples were subjected whole genome sequencing and a haplotype network analysis was performed.Findings Some of the primary clusters identified during January and February in Japan directly descended from Wuhan-Hu-1-related isolates in China and other distinct clusters. Clusters were almost contained until mid-March; the haplotype network analysis demonstrated that COVID-19 cases from late March through early April may have caused an additional large cluster related to the outbreak in Europe, leading to additional spread within Japan. National self-restraint during February was effective in mitigating the COVID-19 spread, but late action on stopping immigration and declaring national emergency in Japan might be involved in the later increase in cases.Interpretation Genome surveillance suggested that at least two distinct SARS-CoV-2 introductions from China and other countries occurred.Funding Japan Agency for Medical Research and Development.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trial. Not available.Clinical Protocols https://www.gisaid.org/epiflu-applications/next-hcov-19-app/ Funding StatementThis study was supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103, JP19fk0108103 and JP19fk0108104.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the National Institute of Infectious Diseases in Japan (Approval No. 1091). It was conducted according to the principles of the Declaration of Helsinki, in compliance with the Law Concerning the Prevention of Infections and Medical Care for Patients of Infections of Japan. The ethical committee waived the need for written consent since the study involved the viral genome sequencing. The personal data related to the clinical information were anonymised, and our procedure is to not request written consent for all patients with COVID-19.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe new sequences have been deposited in Global Initiative on Sharing All Influenza Data (GISAID) with accession IDs EPI_ISL_479792 to EPI_ISL_480227 (Table S2). https://www.gisaid.org/epiflu-applications/next-hcov-19-app/